| |
| |
| Exchange: |
N/A |
| Security
Type: |
N/A |
| Shares
Out: |
82,625,000 |
| Market
Cap: |
175.17(M) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$1.59 - $5.45 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Coherus BioSciences is a commercial-stage biopharmaceutical company focused on the research, development and commercialization of immunotherapies to treat cancer. Co. in-licensed its lead immuno-oncology product candidate, toripalimab (CHS-007), an anti-PD-1 antibody, from Shanghai Junshi Biosciences Co., Ltd. Toripalimab is being evaluated in late-stage clinical trials for the treatment of a range of tumor types. Co.'s commercial portfolio includes two U.S. Food and Drug Administration-approved biologics, including UDENYCA® (pegfilgrastim-cbqv), a biosimilar to Neulasta®, a granulocyte-colony stimulating factor and YUSIMRY™ (adalimumab-aqvh), its Humira® (adalimumab) biosimilar product.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
0 |
223,100 |
223,100 |
223,100 |
| Total Sell Value |
$0 |
$449,770 |
$449,770 |
$449,770 |
| Total People Sold |
0 |
1 |
1 |
1 |
| Total Sell Transactions |
0 |
1 |
1 |
1 |
| End Date |
2024-02-18 |
2023-11-17 |
2023-05-19 |
2022-05-19 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Troendle August J. |
Director |
– • – |
2016-02-09 |
4 |
OE |
$0.42 |
$3,386 |
D/D |
8,124 |
29,994 |
|
- |
|
| Herman Alan C. |
Chief Scientific Officer |
• – – |
2016-02-05 |
4 |
AS |
$15.02 |
$30,040 |
D/D |
(2,000) |
221,615 |
|
- |
|
| Herman Alan C. |
Chief Scientific Officer |
• – – |
2015-12-23 |
4 |
OE |
$0.42 |
$6,669 |
D/D |
16,000 |
227,865 |
|
- |
|
| Herman Alan C. |
Chief Scientific Officer |
• – – |
2015-12-01 |
4 |
AS |
$28.80 |
$334,197 |
D/D |
(11,333) |
211,865 |
|
- |
|
| Herman Alan C. |
Chief Scientific Officer |
• – – |
2015-12-01 |
4 |
OE |
$0.42 |
$3,542 |
D/D |
8,499 |
223,198 |
|
- |
|
| Lanfear Dennis M |
President and CEO |
• • – |
2015-11-30 |
4 |
AS |
$31.75 |
$12,700 |
I/I |
(400) |
1,344,526 |
|
- |
|
| Watler Peter K. |
Chief Technical Officer |
• – – |
2015-11-20 |
4 |
AS |
$27.41 |
$548,178 |
I/I |
(20,000) |
0 |
|
- |
|
| Watler Peter K. |
Chief Technical Officer |
• – – |
2015-11-20 |
4 |
OE |
$1.42 |
$28,340 |
I/I |
20,000 |
20,000 |
|
- |
|
| Richards Christos |
Director |
– • – |
2015-11-13 |
4 |
S |
$27.38 |
$330,732 |
D/D |
(12,000) |
63,836 |
|
- |
|
| Richards Christos |
Director |
– • – |
2015-11-12 |
4 |
S |
$27.23 |
$81,693 |
D/D |
(3,000) |
75,836 |
|
- |
|
| Herman Alan C. |
Chief Scientific Officer |
• – – |
2015-11-02 |
4 |
AS |
$28.65 |
$528,689 |
D/D |
(18,416) |
214,699 |
|
- |
|
| Herman Alan C. |
Chief Scientific Officer |
• – – |
2015-11-02 |
4 |
OE |
$0.42 |
$7,676 |
D/D |
18,416 |
233,115 |
|
- |
|
| Fmr Corp |
10% Owner |
– – • |
2015-10-22 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
510,194 |
|
- |
|
| Herman Alan C. |
Chief Scientific Officer |
• – – |
2015-10-01 |
4 |
AS |
$18.83 |
$80,644 |
D/D |
(4,250) |
214,699 |
|
- |
|
| Herman Alan C. |
Chief Scientific Officer |
• – – |
2015-10-01 |
4 |
OE |
$0.42 |
$1,771 |
D/D |
4,250 |
218,949 |
|
- |
|
| Herman Alan C. |
Chief Scientific Officer |
• – – |
2015-09-01 |
4 |
AS |
$27.23 |
$310,393 |
D/D |
(11,333) |
214,699 |
|
- |
|
| Herman Alan C. |
Chief Scientific Officer |
• – – |
2015-09-01 |
4 |
OE |
$0.42 |
$4,724 |
D/D |
11,333 |
226,032 |
|
- |
|
| Wahlstrom Mats |
Director |
– • – |
2015-08-18 |
4/A |
S |
$33.50 |
$213,475 |
I/I |
(6,372) |
578,528 |
|
- |
|
| Wahlstrom Mats |
Director |
– • – |
2015-08-18 |
4 |
S |
$33.50 |
$213,508 |
I/I |
(6,373) |
578,527 |
|
- |
|
| Wahlstrom Mats |
Director |
– • – |
2015-08-17 |
4 |
S |
$33.91 |
$272,225 |
I/I |
(8,028) |
584,900 |
|
- |
|
| Fmr Corp |
10% Owner |
– – • |
2015-08-14 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
510,194 |
|
- |
|
| Wahlstrom Mats |
Director |
– • – |
2015-08-14 |
4 |
S |
$34.24 |
$3,990,378 |
I/I |
(116,554) |
592,928 |
|
- |
|
| Herman Alan C. |
Chief Scientific Officer |
• – – |
2015-08-03 |
4 |
AS |
$34.83 |
$493,413 |
D/D |
(14,166) |
214,699 |
|
- |
|
| Herman Alan C. |
Chief Scientific Officer |
• – – |
2015-08-03 |
4 |
OE |
$0.42 |
$5,904 |
D/D |
14,166 |
228,865 |
|
- |
|
| Troendle August J. |
Director |
– • – |
2015-07-30 |
4 |
AS |
$32.22 |
$11,504,564 |
I/I |
(340,000) |
268,428 |
|
- |
|
312 Records found
|
|
Page 11 of 13 |
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
| |
OE |
- Options Exercised |
A |
- Acquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
0.05 (2.3%) 
